Cancer risks in Jewish male BRCA1 and BRCA2 mutation carriers

Breast Cancer Research and Treatment
Yael LaitmanEitan Friedman

Abstract

Cancer risks and tumor types in male BRCA1 and BRCA2 mutation carriers are still unsettled. Cancer risks in men who were found to harbor a BRCA1 (n = 150) or a BRCA2 (n = 88) mutation or both (n = 2) were assessed by cross referencing with data on cancer occurrence in the Israeli National Cancer Registry. Incidence rates in mutation carriers were compared with men who were counseled, genotyped, and found not to harbor the familial mutation (true negative n = 122), and with standardized incidence rates (SIRs). Of 210 cancer-free individuals at initial counseling, 11 cancers were diagnosed after a mean follow-up of 5.06 ± 4.1 years (1064 person/years) compared with 1/122 in a BRCA true-negative man. The SIR for all BRCA1/2 mutation carriers compared with the rates in the general population were elevated for pancreatic cancer [2.97 (95 % CI 1.83-4.29)] and breast cancer [16.44 (95 % CI 9.65-26.24)]. For prostate cancer these rates were 0.59 (95 % CI 0.4-0.84). Jewish BRCA1/2 mutation carriers are at an increased risk for breast and pancreatic, but not prostate cancer. These cancer risks and the consequent recommendations, if validated, should be transmitted to carriers at test result disclosure.

References

Aug 5, 1999·Journal of the National Cancer Institute·UNKNOWN Breast Cancer Linkage Consortium
Sep 19, 2002·Journal of the National Cancer Institute·Deborah ThompsonUNKNOWN Breast Cancer Linkage Consortium
Dec 11, 2002·American Journal of Human Genetics·Stephen M EdwardsUNKNOWN British Association of Urological Surgeons Section of Oncology
Feb 18, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alexander LiedeSteven A Narod
May 8, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Tomas KirchhoffKenneth Offit
May 8, 2004·Familial Cancer·Jan LubinskiSteven A Narod
Dec 7, 2006·Journal of the National Cancer Institute·Harvey A RischSteven A Narod
Feb 10, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ilir AgalliuElaine A Ostrander
Nov 29, 2007·Journal of the National Cancer Institute·Yu Chuan TaiSining Chen
Dec 20, 2007·European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (ECP)·Cezary CybulskiJan Lubiński
Mar 11, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·David J GallagherKenneth Offit
Jul 1, 2010·Journal of Medical Genetics·D G R EvansF Lalloo
Apr 5, 2011·Journal of Mammary Gland Biology and Neoplasia·Andrew Y Shuen, William D Foulkes
Mar 9, 2012·Breast Cancer Research and Treatment·Yael LaitmanEitan Friedman
Nov 9, 2012·Gut·Marcia Irene CantoUNKNOWN International Cancer of Pancreas Screening (CAPS) Consortium
Dec 26, 2013·Oncology Nursing Forum·Suzanne M Mahon
Jul 18, 2014·World Journal of Gastrointestinal Endoscopy·Gabriele LamiAndrea Galli
Sep 17, 2014·Cancer·Jacqueline MerschJennifer K Litton

❮ Previous
Next ❯

Citations

May 18, 2019·Andrology·G A KanakisN Jørgensen
Mar 15, 2019·British Journal of Cancer·Tsuyoshi HamadaBrian M Wolpin
Jan 21, 2021·European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (ECP)·Margherita PizzatoCarlo La Vecchia
Oct 14, 2021·Breast Cancer Research and Treatment·Reem S ChamseddineKevin S Hughes

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer: BRCA1 & BRCA2

Mutations involving BRCA1, found on chromosome 17, and BRCA2, found on chromosome 13, increase the risk for specific cancers, such as breast cancer. Discover the last research on breast cancer BRCA1 and BRCA2 here.

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.